Related Experiment Video
Updated: Aug 19, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Nucleoside/nucleotide reverse transcriptase inhibitor drug interactions
Yohan P Samarasinghe1, Marta Boffito, Giovanni Di Perri
1PK Research-St. Stephen's Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK.
Abstract:
Since their advent the nucleoside and nucleotide reverse transcriptase inhibitors have consolidated their position as the 'backbone' of many antiretroviral therapy regimens. The ability of this class of drugs to combine successfully with members of their own as well as other antiretroviral classes has enabled the effective suppression of HIV replication to occur. Many of these therapeutic combinations rely on synergistic interactions to achieve this. There are, however, also many unfavourable pharmacokinetic and pharmacodynamic interactions between the members of nucleoside/nucleotide reverse transcriptase inhibitors, as well as with other antiretroviral classes and non-HIV drugs. This article aims to identify clinically relevant, beneficial and detrimental interactions of this class of antiretroviral agent.
More Related Videos
Related Concept Videos
Antiviral Nucleoside Inhibitors
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacokinetics: Drug–Drug Interactions
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis

